留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

应中央军委要求,2022年9月起,《药学实践杂志》将更名为《药学实践与服务》,双月刊,正文96页;2023年1月起,拟出版月刊,正文64页,数据库收录情况与原《药学实践杂志》相同。欢迎作者踊跃投稿!

双氢青蒿素抗癌药理作用机制的研究进展

周许薇 谭蔚锋 解方园 辛宝 陈俊

周许薇, 谭蔚锋, 解方园, 辛宝, 陈俊. 双氢青蒿素抗癌药理作用机制的研究进展[J]. 药学实践与服务, 2019, 37(3): 206-211,278. doi: 10.3969/j.issn.1006-0111.2019.03.003
引用本文: 周许薇, 谭蔚锋, 解方园, 辛宝, 陈俊. 双氢青蒿素抗癌药理作用机制的研究进展[J]. 药学实践与服务, 2019, 37(3): 206-211,278. doi: 10.3969/j.issn.1006-0111.2019.03.003
ZHOU Xuwei, TAN Weifeng, XIE Fangyuan, XIN Bao, CHEN Jun. Research progress on anti-tumor mechanisms of dihydroartemisinin[J]. Journal of Pharmaceutical Practice and Service, 2019, 37(3): 206-211,278. doi: 10.3969/j.issn.1006-0111.2019.03.003
Citation: ZHOU Xuwei, TAN Weifeng, XIE Fangyuan, XIN Bao, CHEN Jun. Research progress on anti-tumor mechanisms of dihydroartemisinin[J]. Journal of Pharmaceutical Practice and Service, 2019, 37(3): 206-211,278. doi: 10.3969/j.issn.1006-0111.2019.03.003

双氢青蒿素抗癌药理作用机制的研究进展

doi: 10.3969/j.issn.1006-0111.2019.03.003

Research progress on anti-tumor mechanisms of dihydroartemisinin

  • 摘要: 双氢青蒿素是青蒿素的一种重要衍生物,是我国自行研发的抗疟新药。近年来,人们发现双氢青蒿素不但具有抗疟活性,而且具有良好的抗肿瘤效果,被认为是前景良好的抗肿瘤药。因此,综述目前双氢青蒿素抗肿瘤作用发生机制、靶点和通路的研究进展,主要包括癌细胞凋亡、内质网应激、癌细胞生长增殖、侵袭转移、肿瘤多药耐药以及细胞氧化损伤等方面。为抗肿瘤的基础研究、新药物研发以及药物设计提供参考和依据。
  • [1] WONG Y K,XU C,KALESH K A,et al.Artemisinin as an anticancer drug:recent advances in target profiling and mechanisms of action[J].Med Res Rev,2017,37(6):1492-1517.
    [2] 郭宗儒.青蒿素类抗疟药的研制[J].药学学报,2016,51(1):157-164.
    [3] LU J J,MENG L H,SHANKAVARAM U T,et al.Dihydroartemisinin accelerates c-MYC oncoprotein degradation and induces apoptosis in c-MYC-overexpressing tumor cells[J].Biochem Pharmacol,2010,80(1):22-30.
    [4] LIANG S,SUN K,WANG Y,et al.Role of Cyt-C/caspases-9,3,Bax/Bcl-2 and the FAS death receptor pathway in apoptosis induced by zinc oxide nanoparticles in human aortic endothelial cells and the protective effect by alpha-lipoic acid[J].Chem Biol Interact,2016,258:40-51.
    [5] HE Q,SHI J,SHEN X L,et al.Dihydroartemisinin upregulates death receptor 5 expression and cooperates with TRAIL to induce apoptosis in human prostate cancer cells[J].Cancer Biol Ther,2010,9(10):819-824.
    [6] KONG R,JIA G,CHENG Z X,et al.Correction:dihydroartemisinin enhances Apo2L/TRAIL-mediated apoptosis in pancreatic cancer cells via ROS-mediated up-regulation of death receptor 5[J].Plos ONE,2012,7(5):e37222.
    [7] LI Y W,ZHANG W,XU N,et al.Dihydroartemisinin inhibits proliferation of pancreatic cancer JF-305 cells by regulating expression of apoptosis related proteins and production of reactive oxygen species[J].Zhongguo Zhong Yao Za Zhi,2017,42(15):3026-3030.
    [8] ZUO Z J,WANG S T,JIANG L X,et al.Effect of dihydroartemisinin combined irradiation on the apoptosis of human lung cancer GLC-82 cells and its mechanism study[J].Zhongguo Zhong XI Yi Jie He Za Zhi,2014,34(10):1220-1224.
    [9] LU M,SUN L,ZHOU J,et al.Dihydroartemisinin-induced apoptosis is associated with inhibition of sarco/endoplasmic reticulum calcium ATPase activity in colorectal cancer[J].Cell Biochem Biophys,2015,73(1):137-145.
    [10] QIN G,ZHAO C,ZHANG L,et al.Dihydroartemisinin induces apoptosis preferentially via a Bim-mediated intrinsic pathway in hepatocarcinoma cells[J].Apoptosis,2015,20(8):1072-1086.
    [11] LIAO K,LI J,WANG Z.Dihydroartemisinin inhibits cell proliferation via AKT/GSK3β/cyclinD1 pathway and induces apoptosis in A549 lung cancer cells[J].Int J Clin Exp Pathol,2014,7(12):8684.
    [12] FASANO E,SERINI S,PICCIONI E,et al.DHA induces apoptosis by altering the expression and cellular location of GRP78 in colon cancer cell lines[J].Biochim Biophys Acta,2012,1822(11):1762-1772.
    [13] CHEN S S,HU W,WANG Z,et al.p8 attenuates the apoptosis induced by dihydroartemisinin in cancer cells through promoting autophagy[J].Cancer Biol Ther,2015,16(5):770-779.
    [14] CHEN M,CHEN T S,LU Y Y,et al.Dihydroarteminsin-induced apoptosis is not dependent on the translocation of Bim to the endoplasmic reticulum in human lung adenocarcinoma cells[J].Pathol Oncol Res,2012,18(4):809-816.
    [15] ZHANG C,SYED T W,LIU R,et al.Role of endoplasmic reticulum stress,autophagy,and inflammation in cardiovascular disease[J].Front Cardiovasc Med,2017,4:29.
    [16] DU X X,LI Y J,WU C L,et al.Initiation of apoptosis,cell cycle arrest and autophagy of esophageal cancer cells by dihydroartemisinin[J].Biomed Pharmac,2013,67(5):417-424.
    [17] MARCINIAK S J,RON D.Endoplasmic reticulum stress signaling in disease[J].Physiol Rev,2006,86(4):1133-1149.
    [18] SCHRÖDER M.Endoplasmic reticulum stress responses[J].Cell Mol Life Sci,2008,65(6):862-894.
    [19] WANG M,KAUFMAN R J.Protein misfolding in the endoplasmic reticulum as a conduit to human disease[J].Nature,2016,529(7586):326-335.
    [20] HANAHAN D,WEINBERG R A.Hallmarks of cancer:the next generation[J].Cell,2011,144(5):646-674.
    [21] INGHAM M,SCHWARTZ G K.Biology of neoplasia:cell-cycle therapeutics come of age[J].J Clin Oncol,2017,35(25):2949-2959.
    [22] MAGENTA D,SANGIOVANNI E,BASILICO N,et al.Inhibition of metalloproteinase-9 secretion and gene expression by artemisinin derivatives[J].Acta Trop,2014,140:77-83.
    [23] LIN R,ZHANG Z,CHEN L,et al.Dihydroartemisinin (DHA) induces ferroptosis and causes cell cycle arrest in head and neck carcinoma cells[J].Cancer Lett,2016,381(1):165-175.
    [24] TONG Y,LIU Y,ZHENG H,et al.Artemisinin and its derivatives can significantly inhibit lung tumorigenesis and tumor metastasis through Wnt/β-catenin signaling[J].Oncotarget,2016,7(21):31413-31428.
    [25] MI Y,GENG G,ZOU Z,et al.Dihydroartemisinin inhibits glucose uptake and cooperates with glycolysis inhibitor to induce apoptosis in non-small cell lung carcinoma cells[J].PloS ONE,2015,10(3):e0120426.
    [26] ALASEEM A,ALHAZZANI K,Dondapati P,et al.Matrix metalloproteinases:a challenging paradigm of cancer management[J].Semin Cancer Biol,2017,Epub.
    [27] SHAO Y Y,ZHANG T L,WU L X,et al.AKT Axis,miR-21,and RECK play pivotal roles in dihydroartemisinin killing malignant glioma cells[J].Int J Mol Sci,2017,18(2):350.
    [28] HWANG Y P,YUN H J,KIM H G,et al.Suppression of PMA-induced tumor cell invasion by dihydroartemisinin via inhibition of PKCalpha/Raf/MAPKs and NF-kappaB/AP-1-dependent mechanisms[J].Biochem Pharmacol,2010,79(12):1714-1726.
    [29] HU C J,ZHOU L,CAI Y.Dihydroartemisinin induces apoptosis of cervical cancer cells via upregulation of RKIP and downregulation of bcl-2[J].Cancer Biol Ther,2014,15(3):279-288.
    [30] CHEN J,CHEN X,WANG F,et al.Dihydroartemisinin suppresses glioma proliferation and invasion via inhibition of the ADAM17 pathway[J].Neurol Sci,2015,36(3):435-440.
    [31] WANG S J,SUN B,CHENG Z X,et al.Dihydroartemisinin inhibits angiogenesis in pancreatic cancer by targeting the NF-κB pathway[J].Cancer Chemother Pharmacol,2011,68(6):1421.
    [32] PILATI P,NITTI D,MOCELLIN S.Cancer resistance to type Ⅱ topoisomerase inhibitors[J].Curr Med Chem,2012,19(23):3900-3906.
    [33] WIJDEVEN R H,PANG B,ASSARAF Y G,et al.Old drugs,novel ways out:Drug resistance toward cytotoxic chemotherapeutics[J].Drug Resist Updat,2016,28:65-81.
    [34] ONTIKATZE T,RUDNER J,HANDRICK R,et al.Dihydroartemisinin is a hypoxia-active anti-cancer drug in colorectal carcinoma cells[J].Front Oncol,2014,4:116.
    [35] CARO J T,MARíN L M,IAZBIK M C,et al.Markers of iron metabolism in retired racing greyhounds with and without osteosarcoma[J].Vet Clin Pathol,2013,42(3):360-363.
    [36] JIA L,SONG Q,ZHOU C,et al.Dihydroartemisinin as a putative STAT3 inhibitor,suppresses the growth of head and neck squamous cell carcinoma by targeting Jak2/STAT3 signaling[J].PloS ONE,2016,11(1):e0147157.
    [37] CAO L,DUANMU W,YIN Y,et al.Dihydroartemisinin exhibits anti-glioma stem cell activity through inhibiting p-AKT and activating caspase-3[J].Pharmazie,2014,69(10):752-758.
  • [1] 郭灵怡, 刘艳超, 高路, 刘瑞瑶, 吕权真, 俞媛.  醋酸卡泊芬净单硬脂酸甘油酯纳米粒抗白色念珠菌感染的增效作用研究 . 药学实践与服务, 2024, 42(): 1-8. doi: 10.12206/j.issn.2097-2024.202310043
    [2] 丁华敏, 郭羽晨, 秦春霞, 宋志兵, 孙莉莉.  消风止痒颗粒通过降低白三烯水平对小鼠特应性皮炎急性瘙痒的治疗作用研究 . 药学实践与服务, 2024, 42(5): 211-216. doi: 10.12206/j.issn.2097-2024.202306031
    [3] 张艺昕, 关欣怡, 王博宁, 闻俊, 洪战英.  二氢吡啶类钙离子拮抗药物手性分析及其立体选择性药动学研究进展 . 药学实践与服务, 2024, 42(8): 319-324. doi: 10.12206/j.issn.2097-2024.202308062
    [4] 杨媛媛, 安晓强, 许佳捷, 江键, 梁媛媛.  正极性驻极体联合5-氟尿嘧啶对瘢痕成纤维细胞生长抑制的协同作用 . 药学实践与服务, 2024, 42(6): 244-247. doi: 10.12206/j.issn.2097-2024.202310027
    [5] 夏哲炜, 曾垣烨, 朱海菲, 李育, 陈啸飞.  核磁共振磷谱法测定磷酸氢钙咀嚼片中药物含量 . 药学实践与服务, 2024, 42(9): 399-401, 406. doi: 10.12206/j.issn.2097-2024.202404063
    [6] 张修平, 田家盛, 王道鑫, 李佳鑫, 王品, 缪朝玉.  MT-1207对小鼠血糖、血脂和动脉粥样硬化的作用 . 药学实践与服务, 2024, 42(11): 487-494. doi: 10.12206/j.issn.2097-2024.202306011
    [7] 钱淑雨, 李铁军.  耐碳青霉烯类肠杆菌耐药机制的研究进展 . 药学实践与服务, 2024, 42(10): 419-425. doi: 10.12206/j.issn.2097-2024.202405005
    [8] 杨彬, 王作君, 陈菡, 张敬一.  基于DRGs的医院合理用药管理机制探索实践 . 药学实践与服务, 2024, 42(): 1-5. doi: 10.12206/j.issn.2097-2024.202404030
    [9] 徐飞, 陈瑾, 鲁育含, 李志勇.  肠道菌群参与糖尿病肾病的机制研究进展 . 药学实践与服务, 2024, 42(5): 181-184, 197. doi: 10.12206/j.issn.2097-2024.202312023
    [10] 陈莹, 许子华, 胡北, 崔亚玲, 高欢, 吴琼.  通便灵胶囊治疗便秘的药效与机制研究 . 药学实践与服务, 2024, 42(): 1-7. doi: 10.12206/j.issn.2097-2024.202404008
    [11] 舒飞, 孙蕊, 宋凯, 张元林, 闫家铭, 舒丽芯.  粉-液双室袋产品综合评估 . 药学实践与服务, 2024, 42(): 1-5. doi: 10.12206/j.issn.2097-2024.202312009
    [12] 赖立勇, 夏天爽, 徐圣焱, 蒋益萍, 岳小强, 辛海量.  中药青蒿抗氧化活性的谱效关系研究 . 药学实践与服务, 2024, 42(5): 203-210, 216. doi: 10.12206/j.issn.2097-2024.202211012
    [13] 张广雨, 杜晶, 刘梦珍, 朱丹妮, 闫慧, 刘冲.  新斯的明与山莨菪碱联合应用对肺型氧中毒的保护作用及其机制的研究 . 药学实践与服务, 2024, 42(10): 433-438, 444. doi: 10.12206/j.issn.2097-2024.202310049
    [14] 岳春华, 贲永光, 王海桥.  基于NLRP1炎症小体探讨百合知母汤抗抑郁的作用机制 . 药学实践与服务, 2024, 42(8): 325-333. doi: 10.12206/j.issn.2097-2024.202401033
    [15] 修建平, 杨朝爱, 刘禧澳, 潘乾禹, 韦广旭, 王卫星.  全反式维甲酸对肝星状细胞活化及氧化应激的作用和机制探索 . 药学实践与服务, 2024, 42(7): 291-296. doi: 10.12206/j.issn.2097-2024.202312054
    [16] 姜涛, 徐卫凡, 蒋益萍, 夏天爽, 辛海量.  巴戟天丸组方对Aβ损伤成骨细胞的作用及基于网络药理学的机制研究 . 药学实践与服务, 2024, 42(7): 285-290, 296. doi: 10.12206/j.issn.2097-2024.202305011
    [17] 景凯, 杨慈荣, 张圳, 臧艺蓓, 刘霞.  黄芪甲苷衍生物治疗慢性心力衰竭小鼠的药效评价及作用机制研究 . 药学实践与服务, 2024, 42(5): 190-197. doi: 10.12206/j.issn.2097-2024.202310004
    [18] 李清, 郭宜银, 陈颖, 瞿发林, 董文燊, 戈煜.  夜宁胶囊对小鼠镇静催眠作用及其机制的研究 . 药学实践与服务, 2024, 42(8): 346-349. doi: 10.12206/j.issn.2097-2024.202211047
    [19] 张林晨, 张小琴, 张俊平.  山楂酸药理作用的研究进展 . 药学实践与服务, 2024, 42(5): 185-189. doi: 10.12206/j.issn.2097-2024.202307052
    [20] 陈静, 何瑞华, 翁月, 徐熠, 刘静, 黄瑾.  基于网络药理学和分子对接技术探究定清片活性成分治疗白血病的作用机制 . 药学实践与服务, 2024, 42(11): 479-486. doi: 10.12206/j.issn.2097-2024.202401073
  • 加载中
计量
  • 文章访问数:  5919
  • HTML全文浏览量:  1078
  • PDF下载量:  428
  • 被引次数: 0
出版历程
  • 收稿日期:  2018-09-28
  • 修回日期:  2019-01-25

双氢青蒿素抗癌药理作用机制的研究进展

doi: 10.3969/j.issn.1006-0111.2019.03.003

摘要: 双氢青蒿素是青蒿素的一种重要衍生物,是我国自行研发的抗疟新药。近年来,人们发现双氢青蒿素不但具有抗疟活性,而且具有良好的抗肿瘤效果,被认为是前景良好的抗肿瘤药。因此,综述目前双氢青蒿素抗肿瘤作用发生机制、靶点和通路的研究进展,主要包括癌细胞凋亡、内质网应激、癌细胞生长增殖、侵袭转移、肿瘤多药耐药以及细胞氧化损伤等方面。为抗肿瘤的基础研究、新药物研发以及药物设计提供参考和依据。

English Abstract

周许薇, 谭蔚锋, 解方园, 辛宝, 陈俊. 双氢青蒿素抗癌药理作用机制的研究进展[J]. 药学实践与服务, 2019, 37(3): 206-211,278. doi: 10.3969/j.issn.1006-0111.2019.03.003
引用本文: 周许薇, 谭蔚锋, 解方园, 辛宝, 陈俊. 双氢青蒿素抗癌药理作用机制的研究进展[J]. 药学实践与服务, 2019, 37(3): 206-211,278. doi: 10.3969/j.issn.1006-0111.2019.03.003
ZHOU Xuwei, TAN Weifeng, XIE Fangyuan, XIN Bao, CHEN Jun. Research progress on anti-tumor mechanisms of dihydroartemisinin[J]. Journal of Pharmaceutical Practice and Service, 2019, 37(3): 206-211,278. doi: 10.3969/j.issn.1006-0111.2019.03.003
Citation: ZHOU Xuwei, TAN Weifeng, XIE Fangyuan, XIN Bao, CHEN Jun. Research progress on anti-tumor mechanisms of dihydroartemisinin[J]. Journal of Pharmaceutical Practice and Service, 2019, 37(3): 206-211,278. doi: 10.3969/j.issn.1006-0111.2019.03.003
参考文献 (37)

目录

    /

    返回文章
    返回